Corbus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRBP)

$7.95 -0.15 (-1.85 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$7.95
Today's Range$7.90 - $8.35
52-Week Range$5.30 - $10.50
Volume1.02 million shs
Average Volume1.14 million shs
Market Capitalization$442.05 million
P/E Ratio-12.82
Dividend YieldN/A
Beta151.35

About Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals logoCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CRBP
CUSIPN/A
Phone+1-617-9630103

Debt

Debt-to-Equity RatioN/A
Current Ratio6.00%
Quick Ratio6.00%

Price-To-Earnings

Trailing P/E Ratio-12.8225806451613
Forward P/E Ratio-13.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.91 million
Price / Sales231.42
Cash FlowN/A
Price / CashN/A
Book Value$0.20 per share
Price / Book39.75

Profitability

Trailing EPS($0.62)
Net Income$-19,990,000.00
Net Margins-1,040.41%
Return on Equity-96.02%
Return on Assets-77.38%

Miscellaneous

Employees25
Outstanding Shares55,600,000

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The biopharmaceutical company earned $0.80 million during the quarter. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. View Corbus Pharmaceuticals' Earnings History.

Where is Corbus Pharmaceuticals' stock going? Where will Corbus Pharmaceuticals' stock price be in 2018?

4 analysts have issued 1 year price targets for Corbus Pharmaceuticals' shares. Their predictions range from $20.00 to $28.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $24.75 in the next year. View Analyst Ratings for Corbus Pharmaceuticals.

Who are some of Corbus Pharmaceuticals' key competitors?

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the folowing people:

  • Mark A. Tepper Ph.D., President, Chief Scientific Officer
  • Yuval Cohen, Chief Executive Officer, Director (Age 54)
  • Sean F. Moran CPA, Chief Financial Officer
  • Barbara White M.D., Chief Medical Officer (Age 64)
  • David P. Hochman, Director (Age 41)
  • Paris Panayiotopoulos, Director (Age 43)
  • Avery W. Catlin CPA, Independent Director (Age 66)
  • Renu Gupta M.D., Independent Director (Age 59)
  • Alan F. Holmer J.D., Independent Director (Age 65)

Who owns Corbus Pharmaceuticals stock?

Corbus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.47%), Millennium Management LLC (1.01%), Raymond James Financial Services Advisors Inc. (0.78%), Geode Capital Management LLC (0.74%), Artal Group S.A. (0.72%) and Sphera Funds Management LTD. (0.67%). Company insiders that own Corbus Pharmaceuticals stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

Who sold Corbus Pharmaceuticals stock? Who is selling Corbus Pharmaceuticals stock?

Corbus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Perceptive Advisors LLC, Metropolitan Life Insurance Co. NY, Raymond James Financial Services Advisors Inc. and Rhumbline Advisers. View Insider Buying and Selling for Corbus Pharmaceuticals.

Who bought Corbus Pharmaceuticals stock? Who is buying Corbus Pharmaceuticals stock?

Corbus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Sphera Funds Management LTD., Artal Group S.A., Jennison Associates LLC, Virtus Fund Advisers LLC, Deutsche Bank AG, Bank of New York Mellon Corp and Geode Capital Management LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

How do I buy Corbus Pharmaceuticals stock?

Shares of Corbus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of Corbus Pharmaceuticals stock can currently be purchased for approximately $7.95.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $442.05 million and generates $1.91 million in revenue each year. The biopharmaceutical company earns $-19,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Corbus Pharmaceuticals employs 25 workers across the globe.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 100 River Ridge Dr, NORWOOD, MA 02062-5030, United States. The biopharmaceutical company can be reached via phone at +1-617-9630103 or via email at [email protected]


MarketBeat Community Rating for Corbus Pharmaceuticals (CRBP)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corbus Pharmaceuticals (NASDAQ:CRBP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.75$24.75$20.75$20.50
Price Target Upside: 211.32% upside211.32% upside202.92% upside236.07% upside

Corbus Pharmaceuticals (NASDAQ:CRBP) Consensus Price Target History

Price Target History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018Raymond James FinancialInitiated CoverageOutperform -> Outperform$24.00HighView Rating Details
12/29/2017Noble FinancialReiterated RatingBuyN/AView Rating Details
12/14/2017Cantor FitzgeraldSet Price TargetOverweight$24.00 -> $28.00MediumView Rating Details
4/3/2017JMP SecuritiesReiterated RatingOutperform$20.00 -> $27.00LowView Rating Details
11/30/2016AegisReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Corbus Pharmaceuticals (NASDAQ:CRBP) Earnings History and Estimates Chart

Earnings by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ CRBP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.16)($0.14)$0.80 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.15)$0.50 million$0.35 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.16)($0.16)$2.50 million$1.29 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.12)($0.18)$1.50 million$0.38 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.12)$1.00 million$0.74 millionViewN/AView Earnings Details
8/15/2016Q216($0.08)($0.11)$1.25 million$0.40 millionViewN/AView Earnings Details
5/16/2016Q116($0.08)($0.08)$0.40 millionViewN/AView Earnings Details
3/29/2016Q4 2015($0.06)($0.06)$1.25 million$0.36 millionViewN/AView Earnings Details
11/10/2015Q315($0.08)($0.06)$0.17 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.06)($0.10)$0.11 millionViewN/AView Earnings Details
5/13/2015Q1 2015($0.05)($0.06)ViewN/AView Earnings Details
2/10/2015Q4 2014($0.03)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Corbus Pharmaceuticals (NASDAQ:CRBP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.6 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

Dividends

Dividend History for Corbus Pharmaceuticals (NASDAQ:CRBP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.90%
Institutional Ownership Percentage: 33.70%
Insider Trades by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)
Institutional Ownership by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017David P HochmanDirectorBuy5,000$6.55$32,750.00459,500View SEC Filing  
11/13/2017David P HochmanDirectorBuy5,000$6.90$34,500.00View SEC Filing  
11/10/2017Barbara WhiteInsiderBuy2,836$7.00$19,852.00174,050View SEC Filing  
11/10/2017David P HochmanDirectorBuy10,000$7.08$70,800.00459,500View SEC Filing  
11/10/2017Sean F MoranCFOBuy1,500$7.04$10,560.00340,910View SEC Filing  
11/10/2017Yuval CohenCEOBuy1,000$7.17$7,170.0058,775View SEC Filing  
8/11/2017Barbara WhiteInsiderBuy2,479$6.05$14,997.95171,214View SEC Filing  
8/11/2017Sean F MoranCFOBuy2,500$5.91$14,775.00339,410View SEC Filing  
8/11/2017Yuval CohenCEOBuy1,695$6.00$10,170.0057,775View SEC Filing  
5/11/2017Barbara WhiteInsiderBuy2,435$6.12$14,902.20168,735View SEC Filing  
5/11/2017David P HochmanDirectorBuy3,400$6.18$21,012.00459,500View SEC Filing  
5/11/2017Sean F MoranCFOBuy3,300$6.14$20,262.00336,910View SEC Filing  
5/11/2017Yuval CohenCEOBuy3,250$6.01$19,532.5056,080View SEC Filing  
3/17/2017Barbara WhiteInsiderBuy4,233$9.49$40,171.17166,300View SEC Filing  
3/13/2017Sean F MoranCFOBuy2,000$9.60$19,200.00333,610View SEC Filing  
12/2/2016Sean F MoranCFOBuy1,500$7.20$10,800.00331,610View SEC Filing  
11/22/2016Alan F HolmerDirectorBuy1,000$7.49$7,490.0022,000View SEC Filing  
11/22/2016Yuval CohenCEOBuy1,340$7.64$10,237.6012,830View SEC Filing  
11/18/2016David P HochmanDirectorBuy10,000$7.00$70,000.00456,100View SEC Filing  
9/8/2016Sean F MoranCFOBuy30,800$5.12$157,696.00330,110View SEC Filing  
8/26/2016Sean F MoranCFOBuy17,900$3.92$70,168.00299,310View SEC Filing  
8/22/2016David P HochmanDirectorBuy1,800$3.77$6,786.00456,100View SEC Filing  
8/18/2016Sean F MoranCFOBuy148,960$3.32$494,547.20216,410View SEC Filing  
8/17/2016Barbara WhiteInsiderBuy38,000$3.15$119,700.00161,067View SEC Filing  
6/8/2016Barbara WhiteInsiderBuy1,935$3.10$5,998.50123,067View SEC Filing  
6/6/2016Yuval CohenCEOBuy1,500$3.34$5,010.0011,490View SEC Filing  
6/1/2016Barbara WhiteInsiderBuy2,570$3.52$9,046.40121,132View SEC Filing  
5/19/2016Sean F MoranCFOBuy27,250$2.37$64,582.50132,450View SEC Filing  
5/18/2016Sean F MoranCFOBuy30,000$2.39$71,700.00105,250View SEC Filing  
5/18/2016Yuval CohenCEOBuy2,125$2.40$5,100.009,990View SEC Filing  
12/11/2015Sean F MoranCFOBuy1,000$1.56$1,560.0075,250View SEC Filing  
12/10/2015Sean F MoranCFOBuy1,000$1.61$1,610.0074,250View SEC Filing  
12/9/2015Sean F MoranCFOBuy1,000$1.67$1,670.0073,250View SEC Filing  
12/8/2015Sean F MoranCFOBuy1,000$1.68$1,680.0072,250View SEC Filing  
12/7/2015Sean F MoranCFOBuy1,000$1.69$1,690.0071,250View SEC Filing  
12/4/2015Sean F MoranCFOBuy1,000$1.72$1,720.0070,250View SEC Filing  
12/2/2015Sean F MoranCFOBuy1,000$1.79$1,790.0069,250View SEC Filing  
11/24/2015Sean F MoranCFOBuy1,500$1.78$2,670.0068,250View SEC Filing  
11/20/2015Sean F MoranCFOBuy1,500$1.70$2,550.0066,750View SEC Filing  
11/19/2015Barbara WhiteInsiderBuy4,000$1.67$6,680.00118,562View SEC Filing  
11/18/2015Sean F MoranCFOBuy1,500$1.71$2,565.0065,250View SEC Filing  
11/17/2015Sean F MoranCFOBuy1,500$1.72$2,580.0063,750View SEC Filing  
11/16/2015Sean F MoranCFOBuy2,000$1.69$3,380.0062,250View SEC Filing  
9/16/2015Sean F MoranCFOBuy5,000$2.12$10,600.0060,250View SEC Filing  
9/15/2015Sean F MoranCFOBuy5,000$2.14$10,700.0055,250View SEC Filing  
9/14/2015Sean F MoranCFOBuy5,000$1.96$9,800.0050,250View SEC Filing  
9/11/2015Sean F MoranCFOBuy5,000$1.85$9,250.0045,250View SEC Filing  
9/3/2015Barbara WhiteInsiderBuy10,000$1.84$18,400.00113,862View SEC Filing  
8/25/2015Barbara WhiteInsiderBuy6,000$1.87$11,220.00103,862View SEC Filing  
8/21/2015Barbara WhiteInsiderBuy10,000$2.05$20,500.0097,862View SEC Filing  
8/21/2015Sean F MoranCFOBuy1,400$2.06$2,884.0040,250View SEC Filing  
8/19/2015Sumner BursteinMajor ShareholderSell200,000$3.04$608,000.003,594,846View SEC Filing  
8/18/2015Barbara WhiteinsiderBuy20,000$1.90$38,000.0087,862View SEC Filing  
8/18/2015Renu GuptaDirectorBuy10,000$1.89$18,900.0015,000View SEC Filing  
8/18/2015Sean F MoranCFOBuy1,000$1.92$1,920.0038,850View SEC Filing  
8/17/2015Avery W CatlinDirectorBuy11,788$1.94$22,868.72View SEC Filing  
8/17/2015Yuval CohenCEOBuy2,100$1.92$4,032.00View SEC Filing  
7/15/2015Sumner BursteinMajor ShareholderSell30,000$2.82$84,600.00View SEC Filing  
6/15/2015Barbara WhiteInsiderBuy2,250$3.25$7,312.50View SEC Filing  
6/12/2015Barbara WhiteInsiderBuy6,000$3.00$18,000.00View SEC Filing  
6/9/2015Avery W CatlinDirectorBuy20,000$3.10$62,000.00View SEC Filing  
6/9/2015Sean F MoranCFOBuy6,500$3.00$19,500.00View SEC Filing  
12/18/2014Sean F MoranCFOBuy18,800$3.36$63,168.00View SEC Filing  
12/17/2014Sean F MoranCFOBuy2,850$3.46$9,861.00View SEC Filing  
12/11/2014Sean F MoranCFOBuy1,000$3.98$3,980.00View SEC Filing  
12/9/2014Sean F MoranCFOBuy1,700$3.98$6,766.00View SEC Filing  
12/4/2014Barbara WhiteInsiderBuy3,300$3.00$9,900.00View SEC Filing  
12/4/2014David P HochmanDirectorBuy1,300$3.05$3,965.00View SEC Filing  
12/4/2014Sean F MoranCFOBuy2,000$3.20$6,400.00View SEC Filing  
12/3/2014Yuval CohenCEOBuy1,000$3.20$3,200.00View SEC Filing  
12/2/2014Sean F MoranCFOBuy1,000$3.03$3,030.00View SEC Filing  
12/1/2014Barbara WhiteInsiderBuy16,448$3.00$49,344.00View SEC Filing  
11/28/2014Barbara WhiteInsiderBuy19,933$3.00$59,799.00View SEC Filing  
11/26/2014Barbara WhiteInsiderBuy13,400$3.00$40,200.00View SEC Filing  
11/26/2014Sean F MoranCFOBuy1,000$3.05$3,050.00View SEC Filing  
11/25/2014Mark TepperInsiderBuy2,000$3.05$6,100.00View SEC Filing  
11/25/2014Sean F MoranCFOBuy3,000$3.05$9,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corbus Pharmaceuticals (NASDAQ CRBP) News Headlines

Source:
DateHeadline
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical ModelCorbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
finance.yahoo.com - February 15 at 3:55 PM
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceCorbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 14 at 3:21 PM
Corbus Pharmaceuticals Holdings Inc (CRBP) Given Consensus Rating of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings Inc (CRBP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 9:22 AM
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare ConferenceCorbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
finance.yahoo.com - February 6 at 3:19 PM
Corbus Pharmaceuticals (CRBP) Cut to Hold at BidaskClubCorbus Pharmaceuticals (CRBP) Cut to Hold at BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
Corbus Is A Buy, But Not For Cystic Fibrosis - Seeking AlphaCorbus Is A Buy, But Not For Cystic Fibrosis - Seeking Alpha
seekingalpha.com - February 2 at 5:43 AM
Corbus Pharma awarded $25M from CF Foundation to support development of lenabasum; shares up 3% premarket - Seeking AlphaCorbus Pharma awarded $25M from CF Foundation to support development of lenabasum; shares up 3% premarket - Seeking Alpha
seekingalpha.com - February 1 at 3:18 PM
Wired News – Cystic Fibrosis Foundation Gets Development Award to Support Corbus Pharma’s Phase-2b Clinical Study of LenabasumWired News – Cystic Fibrosis Foundation Gets Development Award to Support Corbus Pharma’s Phase-2b Clinical Study of Lenabasum
finance.yahoo.com - February 1 at 3:18 PM
Corbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary ... - StreetInsider.comCorbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary ... - StreetInsider.com
www.streetinsider.com - January 31 at 5:49 AM
Pre-Open Movers 01/30: (SMRT) (CALD) (CRBP) Higher; (SMG) (MXIMI) (ESRX) (UNH) Lower (more...) - StreetInsider.comPre-Open Movers 01/30: (SMRT) (CALD) (CRBP) Higher; (SMG) (MXIMI) (ESRX) (UNH) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support ... - BenzingaCorbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support ... - Benzinga
www.benzinga.com - January 30 at 3:18 PM
Corbus Pharma on go to start mid-stage study of lenabasum in cystic fibrosis; shares up 2% after hours - Seeking AlphaCorbus Pharma on go to start mid-stage study of lenabasum in cystic fibrosis; shares up 2% after hours - Seeking Alpha
seekingalpha.com - January 30 at 3:18 PM
Corbus Pharma (CRBP) Secures $25M Development Award from ... - StreetInsider.comCorbus Pharma (CRBP) Secures $25M Development Award from ... - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of LenabasumCorbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
finance.yahoo.com - January 30 at 3:18 PM
Corbus cystic fibrosis drug to get U.S. FDA review on flare-up dataCorbus cystic fibrosis drug to get U.S. FDA review on flare-up data
www.nasdaq.com - January 30 at 5:46 AM
Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary EndpointCorbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
finance.yahoo.com - January 30 at 5:46 AM
Corbus Pharmaceuticals (CRBP) Upgraded by BidaskClub to "Buy"Corbus Pharmaceuticals (CRBP) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 28 at 9:30 AM
4 Drug Stocks to Watch - Nasdaq4 Drug Stocks to Watch - Nasdaq
www.nasdaq.com - January 24 at 3:21 PM
Analysis: Positioning to Benefit within Ferroglobe, Corbus Pharmaceuticals, Meritage, Dicerna Pharmaceuticals, Castle Brands, and Ply Gem — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Ferroglobe, Corbus Pharmaceuticals, Meritage, Dicerna Pharmaceuticals, Castle Brands, and Ply Gem — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - January 24 at 8:31 AM
Why the Medical Marijuana Industry Is GrowingWhy the Medical Marijuana Industry Is Growing
finance.yahoo.com - January 22 at 7:56 AM
Corbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at Raymond James FinancialCorbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at Raymond James Financial
www.americanbankingnews.com - January 20 at 4:08 PM
How Marijuana Acceptance Is Evolving GloballyHow Marijuana Acceptance Is Evolving Globally
finance.yahoo.com - January 19 at 5:46 PM
Cannabis Market Sales on the Rise According to Data - PR Newswire (press release)Cannabis Market Sales on the Rise According to Data - PR Newswire (press release)
www.prnewswire.com - January 10 at 9:38 AM
BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍
www.reuters.com - January 6 at 9:36 AM
Opinion: Harry Boxers four stocks popping to start the new year - MarketWatchOpinion: Harry Boxer's four stocks popping to start the new year - MarketWatch
www.marketwatch.com - January 5 at 5:01 PM
Stock Traders Purchase High Volume of Corbus Pharmaceuticals Call Options (CRBP)Stock Traders Purchase High Volume of Corbus Pharmaceuticals Call Options (CRBP)
www.americanbankingnews.com - January 4 at 3:36 AM
Corbus Pharmaceuticals (CRBP) Buy Rating Reiterated at Noble FinancialCorbus Pharmaceuticals' (CRBP) Buy Rating Reiterated at Noble Financial
www.americanbankingnews.com - December 30 at 6:14 AM
Corbus Pharmaceuticals (CRBP) Rating Increased to Hold at BidaskClubCorbus Pharmaceuticals (CRBP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - December 29 at 11:56 AM
ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : December 26, 2017ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 11:28 AM
Noble Financial Reaffirms Buy Rating for Corbus Pharmaceuticals (CRBP)Noble Financial Reaffirms Buy Rating for Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - December 25 at 1:32 PM
Corbus Pharmaceuticals (CRBP) Stock Rating Lowered by BidaskClubCorbus Pharmaceuticals (CRBP) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 24 at 9:20 AM
Zacks: Analysts Anticipate Corbus Pharmaceuticals Holdings, Inc. (CRBP) to Post -$0.18 EPSZacks: Analysts Anticipate Corbus Pharmaceuticals Holdings, Inc. (CRBP) to Post -$0.18 EPS
www.americanbankingnews.com - December 22 at 7:18 AM
Financial Survey: Corbus Pharmaceuticals (CRBP) versus Its RivalsFinancial Survey: Corbus Pharmaceuticals (CRBP) versus Its Rivals
www.americanbankingnews.com - December 20 at 8:38 AM
Cantor Fitzgerald Analysts Increase Earnings Estimates for Corbus Pharmaceuticals Holdings, Inc. (CRBP)Cantor Fitzgerald Analysts Increase Earnings Estimates for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
www.americanbankingnews.com - December 20 at 8:14 AM
Comparing Corbus Pharmaceuticals (CRBP) and Omeros (OMER)Comparing Corbus Pharmaceuticals (CRBP) and Omeros (OMER)
www.americanbankingnews.com - December 17 at 1:50 PM
Corbus Pharmaceuticals (CRBP) "Buy" Rating Reaffirmed at Noble FinancialCorbus Pharmaceuticals' (CRBP) "Buy" Rating Reaffirmed at Noble Financial
www.americanbankingnews.com - December 16 at 1:34 PM
ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : December 15, 2017ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 5:51 PM
Corbus Pharmaceuticals (CRBP) Given a $28.00 Price Target by Cantor Fitzgerald AnalystsCorbus Pharmaceuticals (CRBP) Given a $28.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 14 at 11:14 AM
30 Stocks Moving In Wednesdays Pre-Market Session - Benzinga30 Stocks Moving In Wednesday's Pre-Market Session - Benzinga
www.benzinga.com - December 13 at 9:52 AM
Reviewing Corbus Pharmaceuticals (CRBP) & Its CompetitorsReviewing Corbus Pharmaceuticals (CRBP) & Its Competitors
www.americanbankingnews.com - December 7 at 5:30 AM
Insight: High tech, high finance and high times for U.S. pot industryInsight: High tech, high finance and high times for U.S. pot industry
finance.yahoo.com - December 6 at 9:46 AM
Comparing Corbus Pharmaceuticals (CRBP) and Its RivalsComparing Corbus Pharmaceuticals (CRBP) and Its Rivals
www.americanbankingnews.com - December 5 at 7:48 AM
Zacks: Analysts Expect Corbus Pharmaceuticals Holdings, Inc. (CRBP) to Announce -$0.18 Earnings Per ShareZacks: Analysts Expect Corbus Pharmaceuticals Holdings, Inc. (CRBP) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - December 4 at 11:42 AM
Corbus Trial Data Piles On As Insiders And Institutional Investors Follow Suit - Seeking AlphaCorbus Trial Data Piles On As Insiders And Institutional Investors Follow Suit - Seeking Alpha
seekingalpha.com - December 1 at 4:55 PM
Cannabis Sales Expected to Grow Due to Medical BenefitsCannabis Sales Expected to Grow Due to Medical Benefits
www.prnewswire.com - November 30 at 10:02 AM
Corbus Pharma (CRBP) Granted Patent Covering Use of Anabasum for Treatment of Rare Fibrotic DiseasesCorbus Pharma (CRBP) Granted Patent Covering Use of Anabasum for Treatment of Rare Fibrotic Diseases
www.streetinsider.com - November 29 at 9:41 AM
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Given Consensus Recommendation of "Hold" by BrokeragesCorbus Pharmaceuticals Holdings, Inc. (CRBP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 7:08 PM
Corbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public OfferingCorbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering
finance.yahoo.com - November 27 at 6:12 PM
Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic DiseasesCorbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
finance.yahoo.com - November 27 at 6:12 PM
Head-To-Head Comparison: Corbus Pharmaceuticals Holdings (CRBP) & Its PeersHead-To-Head Comparison: Corbus Pharmaceuticals Holdings (CRBP) & Its Peers
www.americanbankingnews.com - November 21 at 11:28 PM

SEC Filings

Corbus Pharmaceuticals (NASDAQ:CRBP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corbus Pharmaceuticals (NASDAQ:CRBP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corbus Pharmaceuticals (NASDAQ CRBP) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.